LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Kodu・Aktsiate loetelu・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Suletud

SektorTervishoid

54.89 0.96

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

54.31

Max

55.05

Põhinäitajad
By Trading Economics
Sissetulek	1.6B 2.7B
Müük	-1B 11B
P/E Sektori keskmine	15.392 49.888
Aktsiakasum	1.31
Dividenditootlus	4.37
Kasumimarginaal	23.309
Töötajad	32,500
EBITDA	1.5B 3.7B

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+16.25% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	4.37% 2.38%
Järgmine tulemuste avaldamine	30. juuli 2026
Järgmine dividendimakse kuupäev	31. juuli 2026
Järgmine aktsia dividendi kuupäev (ex-date)	2. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	-5.8B 112B
Eelmine avamishind	53.93
Eelmine sulgemishind	54.89

Bristol-Myers Squibb Co. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. juuni 2026, 13:08 UTC

Tulu

Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial

12. mai 2026, 06:42 UTC

Suurimad hinnamuutused turgudel

Bristol Myers Squibb and China's Hengrui Pharma Forge Tie-Up

30. apr 2026, 11:14 UTC

Tulu

Bristol Myers Squibb Logs Higher 1Q Sales Driven by Growth Portfolio

29. mai 2026, 08:15 UTC

Market Talk

Tulu

Bayer's Key Pharma Products Face Competitive Risk -- Market Talk

5. mai 2026, 18:12 UTC

Tulu

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5. mai 2026, 13:54 UTC

Tulu

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

30. apr 2026, 10:59 UTC

Tulu

Bristol Myers Squibb: Continue to See Total Worldwide Eliquis Revenue Increasing 10%-15% in 2026 Vs Yr-Ago >BMY

30. apr 2026, 10:59 UTC

Tulu

Bristol Myers Squibb: 2026 Guidance Excludes Impact of Any Potential Future Strategic Acquisitions, Divestitures and Impact of Future Acquired IPRD Charges and Licensing Income >BMY

30. apr 2026, 10:59 UTC

Tulu

Bristol Myers Squibb: Reaffirming 2026 Financial Guidance With Total Revenue and Diluted EPS Trending Toward Upper End of Ranges >BMY

30. apr 2026, 10:59 UTC

Tulu

Bristol Myers Squibb Backs 2026 Rev $46B-$47.5B >BMY

30. apr 2026, 10:59 UTC

Tulu

Bristol Myers Squibb 1Q International Revenue Rose 11% to $3.7B >BMY

30. apr 2026, 10:59 UTC

Tulu

Bristol Myers Squibb: 1Q Results Reflecting Sustained Momentum Across Our Growth Portfolio and Disciplined Execution Throughout the Business >BMY

30. apr 2026, 10:59 UTC

Tulu

Bristol Myers Squibb 1Q U.S. Revenue Fell 1% to $7.79B >BMY

30. apr 2026, 10:59 UTC

Tulu

Bristol Myers Squibb 1Q Rev $11.49B >BMY

30. apr 2026, 10:59 UTC

Tulu

Bristol Myers Squibb: In Legacy Portfolio, Demand Increased for Eliquis in 1Q, Which Was More Than Offset by Expected Continued Generic Impacts Across Remainder of Portfolio >BMY

30. apr 2026, 10:59 UTC

Tulu

Bristol Myers Squibb: 1Q Growth Portfolio Revenue Increase Primarily Driven by Reblozyl, Camzyos and Breyanzi >BMY

30. apr 2026, 10:59 UTC

Tulu

Bristol Myers Squibb 1Q Eliquis Revenue Rose 16% to $4.14B >BMY

30. apr 2026, 10:59 UTC

Tulu

Bristol Myers Squibb Backs 2026 Adj EPS $6.05-Adj EPS $6.35 >BMY

30. apr 2026, 10:59 UTC

Tulu

Bristol Myers Squibb 1Q Adjusted Gross Margin 70.3% >BMY

30. apr 2026, 10:59 UTC

Tulu

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 12% to $6.23B >BMY

30. apr 2026, 10:59 UTC

Tulu

Bristol Myers Squibb 1Q EPS $1.31 >BMY

30. apr 2026, 10:59 UTC

Tulu

Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 6% to $5.28B >BMY

30. apr 2026, 10:59 UTC

Tulu

Bristol Myers Squibb 1Q Adj EPS $1.58 >BMY

30. apr 2026, 10:59 UTC

Tulu

Bristol Myers Squibb: Latest 1Q Includes Net Impact of Loss of 3c/Shr Due to Acquired IPRD Charges and Licensing Income >BMY

30. apr 2026, 10:59 UTC

Tulu

Bristol Myers Squibb 1Q Gross Margin 70.2% >BMY

14. apr 2026, 14:13 UTC

Tulu

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14. apr 2026, 12:57 UTC

Tulu

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14. apr 2026, 11:19 UTC

Tulu

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

14. apr 2026, 10:34 UTC

Tulu

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

13. apr 2026, 21:23 UTC

Tulu

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Bristol-Myers Squibb Co. Prognoos

Hinnasiht

By TipRanks

16.25% tõus

12 kuu keskmine prognoos

Keskmine 63.31 USD 16.25%

Kõrge 75 USD

Madal 40 USD

Põhineb 20 Wall Streeti analüütiku instrumendi Bristol-Myers Squibb Co. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

20 ratings

Osta

Hoia

Müü

Põhineb 20 analüütiku instrumendi Bristol-Myers Squibb Co. aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.